1218 related articles for article (PubMed ID: 19111493)
21. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Soriano V
Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
[TBL] [Abstract][Full Text] [Related]
22. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
Oette M; Kaiser R; Däumer M; Akbari D; Fätkenheuer G; Rockstroh JK; Stechel J; Rieke A; Mauss S; Schmalöer D; Göbels K; Vogt C; Wettstein M; Häussinger D
Eur J Med Res; 2004 May; 9(5):273-8. PubMed ID: 15257882
[TBL] [Abstract][Full Text] [Related]
23. Low prevalence of primary HIV resistance in western Massachusetts.
Iarikov DE; Irizarry-Acosta M; Martorell C; Hoffman RP; Skiest DJ
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(4):227-31. PubMed ID: 20798402
[TBL] [Abstract][Full Text] [Related]
24. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.
de Mendoza C; Rodriguez C; Corral A; del Romero J; Gallego O; Soriano V
Clin Infect Dis; 2004 Oct; 39(8):1231-8. PubMed ID: 15486849
[TBL] [Abstract][Full Text] [Related]
25. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
[TBL] [Abstract][Full Text] [Related]
26. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
[TBL] [Abstract][Full Text] [Related]
27. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
[No Abstract] [Full Text] [Related]
28. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
[TBL] [Abstract][Full Text] [Related]
29. Drug resistance mutations during structured treatment interruptions.
Yerly S; Fagard C; Günthard HF; Hirschel B; Perrin L;
Antivir Ther; 2003 Oct; 8(5):411-5. PubMed ID: 14640388
[TBL] [Abstract][Full Text] [Related]
30. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
[TBL] [Abstract][Full Text] [Related]
31. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
32. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities.
Sullivan PS; Buskin SE; Turner JH; Cheingsong R; Saekhou A; Kalish ML; Jones JL; Respess R; Kovacs A; Heneine W
Int J STD AIDS; 2002 Aug; 13(8):554-8. PubMed ID: 12194739
[TBL] [Abstract][Full Text] [Related]
33. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
[TBL] [Abstract][Full Text] [Related]
36. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.
Corvasce S; Violin M; Romano L; Razzolini F; Vicenti I; Galli A; Duca P; Caramma I; Balotta C; Zazzi M
Antivir Ther; 2006; 11(3):329-34. PubMed ID: 16759049
[TBL] [Abstract][Full Text] [Related]
37. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
38. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
40. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]